Olanzapine Versus Clozapine in Treatment Refractory Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00179231
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : September 15, 2005
Information provided by:
Vanderbilt University

Brief Summary:
The study involves a six-month, double-blind protocol during which eighty patients, across three sites around the country, will be randomly assigned to receive clozapine or olanzapine. The specific aims of the study are to evaluate the relative effects of olanzapine and clozapine on clinical outcomes and cognition in patients diagnosed with schizophrenia or schizoaffective disorder who have demonstrated resistance to treatment in the past.

Condition or disease Intervention/treatment Phase
Schizophrenia Schizoaffective Disorder Drug: olanzapine vs. clozapine Not Applicable

Study Type : Interventional  (Clinical Trial)
Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Study Start Date : May 2000
Study Completion Date : February 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Primary Outcome Measures :
  1. There has not been an adequate of test of whether olanzapine is as effective as clozapine in treatment
  2. resistant patients. Several recent studies suggest olanzapine may be effective in some clozapine responders as well as in treatment resistant patients. A head to head comparison is needed to clarify the relative efficacy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients will be males and females, ages 18-60, with a definite diagnosis by DSM-IV criteria of schizophrenia (any subtype) or schizoaffective disorder.
  2. 2) All participants will be refractory according to the Kane et al (1988) criteria, with modification on the number of drug trials to at least two neuroleptic drugs at adequate doses for periods > 3 months. The criteria of Kane et al. for treatment resistance are as follows: three or more trials with antipsychotic drugs of adequate dose and duration (this is usually 4-6 weeks). The original criteria involved three types of typical neuroleptic drugs. Now, it can include any antipsychotic drug other than clozapine. Olanzapine may have been tried but the dose must not have exceeded 30 mg/day.
  3. Subjects must have a PANNS-derived BPRS total score > 24 (0-6 scale) or BPRS positive subscale item score > 3 on at least two of the four items.
  4. Participants will be in generally good and stable physical health.
  5. Written informed consent will be obtained from all participants after a full explanation of the study and procedures. For those patients with a legal guardian, written informed consent will be obtained from the guardian, with verbal assent by the research subject.
  6. Since both clozapine and olanzapine are approved agents, no specific birth control will be required for females, but advice about birth control will be provided

Exclusion Criteria:

  1. Uncontrolled diabetes or hypertension.
  2. Cardiac conduction abnormality or uncontrolled arrhythmia.
  3. History of any blood dyscrasia, including leukemia.
  4. Significant active hepatic or renal disease, including chronic hepatitis.
  5. Clinically significant neurological disorder, including (but not limited to) Parkinson’s disease, multiple sclerosis, seizure disorder, intracranial mass lesion (note that the presence of tardive dyskinesia is not an exclusion for participants).
  6. Active cancer with or without chemotherapy within the last five years (not to include a completely excised basal cell carcinoma).
  7. Active endocrinological disorder (which does not include adequately treated hypothyroidism).
  8. Pregnancy or lactation.
  9. An active substance use disorder within the last six months.
  10. History of lack of response to an adequate trial of monotherapy with either clozapine or olanzapine in which the dose of clozapine must be > 600 mg/day or the dose of olanzapine must be > 20 mg/day; and the duration of treatment with either must be > 6 weeks.
  11. History of intolerance of clozapine or olanzapine, including blood dyscrasia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00179231

Sponsors and Collaborators
Vanderbilt University
Principal Investigator: Herbert Y Meltzer, M.D. Vanderbilt University Medical Center

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00179231     History of Changes
Other Study ID Numbers: 990172
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: September 15, 2005
Last Verified: September 2005

Additional relevant MeSH terms:
Psychotic Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Serotonin Antagonists
GABA Antagonists
GABA Agents